Skip to content
value.today
Olema Pharmaceuticals, Inc. logo

Olema Pharmaceuticals, Inc.

Formerly CombiThera, Inc.

Total raised
$147 M
3 rounds on record
Latest round
$87 M
Sep 2020
First round on record
Jul 2018
Today
Went public
See the company page

Olema Pharmaceuticals, Inc. is listed today as Olema Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Olema Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$250 MPrivate placement after listing$250 million to $1 billion

Olema Pharmaceuticals, Inc.: Private sale, Dec 2024

Investors in this round

26 investors had bought by the notice of Dec 12, 2024: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Olema Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$250 M of $250 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$12,500,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David C. Myles, Ph.D. · Executive Officer
  • Naseem C. Zojwalla, M.D. · Executive Officer
  • Sean Bohen, M.D., Ph.D. · Executive Officer, Director
  • Shane C. Kovacs · Executive Officer
  • Andrew C. Rappaport · Director
  • Cynthia C. Butitta · Director
  • Cyrus L. Harmon, Ph.D. · Director
  • Gorjan L. Hrustanovic, Ph.D. · Director
  • Graham L. Walmsley, M.D., Ph.D. · Director
  • Ian L. Clark · Director
  • Sandra L. Horning, M.D. · Director
  • Scott L. Garland · Director
  • Yi C. Larson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Goldman Sachs & Co. LLC (CRD 361) · New York, New YorkSold in all US states
  • LifeSci Capital LLC (CRD 168404) · New York, New YorkSold in all US states
  • Oppenheimer & Co. Inc. (CRD 249) · New York, New YorkSold in all US states
  • H.C. Wainright & Co., LLChow (CRD 375) · New York, New YorkSold in all US states
  • Citigroup Global Markets Inc. (CRD 7059) · New York, New YorkSold in all US states
  • J.P. Morgan Securities LLC (CRD 79) · New York, New YorkSold in all US states
  • Jefferies LLC (CRD 2347) · New York, New YorkSold in all US states

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Remaining to be Sold include amounts that may be received by the Issuer upon exercise of pre-funded warrants at an exercise price of $0.0001 per pre-funded warrant.”

Signed by Shane Kovacs, Chief Operating and Financial Officer. Source: SEC Form D, newest notice filed Dec 12, 2024. Read the notice at the SEC.

equity, optionsSEC
Sep 2023$130 MPrivate placement after listing$50 to $250 million

Olema Pharmaceuticals, Inc.: Private sale, Sep 2023

Investors in this round

12 investors had bought by the notice of Sep 14, 2023: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Olema Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$130 M of $130 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David C. Myles, Ph.D. · Executive Officer
  • Naseem C. Zojwalla, M.D. · Executive Officer
  • Sean Bohen, M.D., Ph.D. · Executive Officer, Director
  • Shane C. Kovacs · Executive Officer
  • Andrew C. Rappaport · Director
  • Cynthia C. Butitta · Director
  • Cyrus L. Harmon, Ph.D. · Director
  • Gorjan L. Hrustanovic, Ph.D. · Director
  • Graham L. Walmsley, M.D., Ph.D. · Director
  • Ian L. Clark · Director
  • Sandra L. Horning, M.D. · Director
  • Yi C. Larson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shane Kovacs, EVP, Chief Legal Officer and Secretary. Source: SEC Form D, newest notice filed Sep 14, 2023. Read the notice at the SEC.

equitySEC
Sep 2020$87 MNo. 3$50 to $250 million

Olema Pharmaceuticals, Inc.: Raise no. 3, Sep 2020

Investors in this round

27 investors had bought by the notice of Oct 13, 2020: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Olema Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$87 M of $87 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,410,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cyrus Harmon · Executive Officer, Director
  • David Myles · Executive Officer
  • John Moriarty · Executive Officer
  • Kinney Horn · Executive Officer
  • Peter Kushner · Executive Officer
  • Sean Bohen · Executive Officer, Director
  • Shane Kovacs · Executive Officer
  • Andrew Rappaport · Director
  • Cynthia Butitta · Director
  • Frank McCormick · Director
  • Gorjan Hrustanovic · Director
  • Graham Walmsley · Director
  • Ian Clark · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • OM Co-Investment LLC · broker-dealer Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in all US states

Signed by Shane Kovacs, Cfo. Source: SEC Form D, newest notice filed Oct 13, 2020. Read the notice at the SEC.

equitySEC
Mar 2020$54 MNo. 2$50 to $250 million

Olema Pharmaceuticals, Inc.: Raise no. 2, Mar 2020

Investors in this round

16 investors had bought by the notice of Jun 23, 2020: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Olema Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$54 M of $55 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B Preferred stock and Common Stock Issuable upon conversion thereof; Series B Preferred stock issued upon conversion of promissory notes.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cyrus Harmon · Executive Officer, Director
  • Pamela Klein · Executive Officer
  • Peter Kushner · Executive Officer
  • Andrew Rappaport · Director
  • Frank McCormick · Director
  • Gorjan Hrustanovic · Director
  • Graham Walmsley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “(b) includes $3,007,359 attributed to conversion of convertible promissory notes”

Signed by Cyrus L. Harmon, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Jun 23, 2020. Read the notice at the SEC.

equitySEC
Jul 2018$6 MNo. 1$2 to $10 million

Olema Pharmaceuticals, Inc.: Raise no. 1, Jul 2018

Investors in this round

13 investors had bought by the notice of Aug 27, 2018: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Olema Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series A-1 Preferred stock, Series A Preferred Stock, and Common Stock Issuable upon conversion thereof; Common Stock issued upon conversion of promissory notes.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cyrus Harmon · Executive Officer, Director
  • David Myles · Executive Officer
  • Peter Kusher · Executive Officer, Director
  • Andrei Manoliu · Director
  • Andrew Rappaport · Director
  • Frank McCormick · Director
  • Gorjan Hrustanovic · Director
  • Lawrence Fritz · Director
  • Marina Bozilenko · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cyrus L. Harman, Ceo. Source: SEC Form D, newest notice filed Aug 27, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Olema Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2024).

    SEC Form D · Dec 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2024

That is all the official record says: Olema Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Olema Pharmaceuticals, Inc. are on record.

Investors#

17 named in official filings. Open an investor to see everything it has backed.

Investors in Olema Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Biotechnology Value Fund II LPFund or asset managernot statednot statedHeld Series A-1, B and C preferred stock (Form 3, 2020)SEC Form 3
Biotechnology Value Fund L.P.Fund or asset managernot statednot statedHeld Series A-1, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Biotechnology Value Trading Fund OS LPFund or asset managernot statednot statedHeld Series A-1, B and C preferred stock (Form 3, 2020)SEC Form 3
BVF GP Holdings LLCOthernot statednot statedHeld Series A-1, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
BVF I GP LLCOthernot statednot statedHeld Series A-1, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
BVF II GP LLCOthernot statednot statedHeld Series A-1, B and C preferred stock (Form 3, 2020)SEC Form 3
BVF Inc/ilFund or asset managernot statednot statedHeld Series A-1, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
BVF Partners L P/ilFund or asset managernot statednot statedHeld Series A-1, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
BVF Partners OS Ltd.Fund or asset managernot statednot statedHeld Series A-1, B and C preferred stock (Form 3, 2020)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cormorant Private Healthcare Fund III LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cormorant Private Healthcare Fund II, LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cyrus HarmonPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2020)SEC Form 3
Frank McCormickPersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2020)SEC Form 3
Peter J. KushnerPersonnot statednot statedHeld Series A and A-1 preferred stock (Form 3, 2020)SEC Form 3
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 27 investors.

Largest shareholders today

Institutions holding Olema Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Olema Pharmaceuticals, Inc.
NameRoleNamed in
David C. Myles, Ph.D.Executive officerDec 2024
Naseem C. Zojwalla, M.D.Executive officerDec 2024
Sean Bohen, M.D., Ph.D.Executive officerDec 2024
Shane C. KovacsExecutive officerDec 2024
Cyrus HarmonExecutive officerOct 2020
David MylesExecutive officerOct 2020
John MoriartyExecutive officerOct 2020
Kinney HornExecutive officerOct 2020
Peter KushnerExecutive officerOct 2020
Sean BohenExecutive officerOct 2020
Shane KovacsExecutive officerOct 2020
Pamela KleinExecutive officerJun 2020
Frank McCormickExecutive officerMar 2020
Peter KusherExecutive officerAug 2018
Andrew C. RappaportDirectorDec 2024
Cynthia C. ButittaDirectorDec 2024
Cyrus L. Harmon, Ph.D.DirectorDec 2024
Gorjan L. Hrustanovic, Ph.D.DirectorDec 2024
Graham L. Walmsley, M.D., Ph.D.DirectorDec 2024
Ian L. ClarkDirectorDec 2024
Sandra L. Horning, M.D.DirectorDec 2024
Scott L. GarlandDirectorDec 2024
Sean Bohen, M.D., Ph.D.DirectorDec 2024
Yi C. LarsonDirectorDec 2024
Andrew RappaportDirectorOct 2020
Cynthia ButittaDirectorOct 2020
Cyrus HarmonDirectorOct 2020
Frank McCormickDirectorOct 2020
Gorjan HrustanovicDirectorOct 2020
Graham WalmsleyDirectorOct 2020
Ian ClarkDirectorOct 2020
Sean BohenDirectorOct 2020
Gorjan HrustanovichDirectorMar 2020
Andrei ManoliuDirectorAug 2018
Lawrence FritzDirectorAug 2018
Marina BozilenkoDirectorAug 2018
Peter KusherDirectorAug 2018

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.